Company

The Westaim Corporation invests, directly and indirectly, through acquisitions, joint ventures and other arrangements, with the objective of providing its shareholders with capital appreciation and real wealth preservation. Westaim holds a 75 per cent interest in NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS). Westaim's common shares are listed on The Toronto Stock Exchange under the trading symbol WED.

NUCRYST Pharmaceuticals develops, manufactures and commercializes medical products that fight infection and inflammation using its patented atomically disordered nanocrystalline silver technology.

NUCRYST is one of the first companies to successfully launch a medical product based on nanotechnology. Advanced wound care products with the company’s SILCRYST™ coatings are sold by Smith & Nephew plc under an exclusive license in over 30 countries under its Acticoat™ trademark. NUCRYST is also developing innovative pharmaceutical products to address medical conditions that are characterized by both infection and inflammation. 

Building on its profitable SILCRYST business, NUCRYST is developing pharmaceutical products with its nanocrystalline noble metal platform to address medical conditions that are characterized by both infection and inflammation. NUCRYST has developed its nanocrystalline silver in a powder form for use as an active pharmaceutical ingredient, or API, known as NPI 32101.

NUCRYST Pharmaceuticals completed an Initial Public Offering of common shares in 2005. The Westaim Corporation owns 75 per cent of NUCRYST's outstanding shares.